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Abstract 
 
 
Age-related loss of skeletal muscle mass and function, sarcopenia, is associated with 
physical frailty and increased risk of morbidity (chronic diseases), in addition to all-
cause mortality. The loss of muscle mass occurs incipiently from middle-age 
(~1%/year), and in severe instances can lead to a loss of ~50% by the 8-9th decade of 
life. This review will focus on muscle deterioration with ageing and highlight the two 
underpinning mechanisms regulating declines in muscle mass and function: muscle 
fibre atrophy and muscle fibre loss (hypoplasia) – and their measurement. The 
mechanisms of muscle fibre atrophy in humans relate to imbalances in muscle protein 
synthesis (MPS) and breakdown (MPB); however, since there is limited evidence for 
basal alterations in muscle protein turnover, it would appear that “anabolic resistance’ 
to fundamental environmental cues regulating diurnal muscle homeostasis (namely 
physical activity and nutrition), underlie age-related catabolic perturbations in muscle 
proteostasis. While the ‘upstream’ drivers of the desensitization of aged muscle to 
anabolic stimuli are poorly defined, they most likely relate to impaired efficiency of the 
conversion of nutritional/exercise stimuli into signalling impacting mRNA translation 
and proteolysis. Additionally, loss of muscle fibres has been shown in cadaveric 
studies using anatomical fibre counts, and from iEMG studies demonstrating motor 
unit loss, albeit with few molecular investigations of this in humans. We suggest that 
defining countermeasures against sarcopenia requires improved understandings of 
the co-ordinated regulation of muscle fibre atrophy and fibre loss, which are likely to 
be inextricably linked.  
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1. Introduction 
 
Improvements in healthcare and nutrition have led to increased lifespan the developed 
world over, and thus rapid manifestation of an ageing demographic. As a consequence 
of the world’s ageing populace, the prevalence of chronic diseases is also on the 
increase e.g. since chronological age is a major pre-disposing factor to diabetes, 
cardiovascular/respiratory diseases, arthritic diseases and cancers (Coresh et al., 
2003; Driver et al., 2008; Mitchell et al., 2012; Zierer et al., 2016). This has led to 
fervent efforts to develop treatments to limit the development of such chronic diseases, 
using pharmacological and/or lifestyle countermeasures e.g. physical activity and 
dietary modification. While not yet an accepted clinically diagnosable phenomena 
(mainly due to a lack of consensus criteria), muscle mass declines with age in a 
process termed sarcopenia (Mitchell et al., 2012). Longitudinal studies show that in 
people aged ~75y, muscle mass is lost at a rate of 0.64–0.7%/y in women and 0.8–
0.98%/y in men (Mitchell et al., 2012). Muscle function (e.g. using strength-related 
performance as a proxy) is lost more rapidly, with longitudinal studies showing that at 
aged ~75y, strength is lost at a rate of 3–4% per year in men and 2.5–3% per year in 
women (Mitchell et al., 2012). It is beyond the scope of this review to outline the ever 
evolving recommendations for diagnostic criteria and prevalence of sarcopenia; 
instead readers are directed to detailed reviews from the European Working Group on 
Sarcopenia in Older People (EWGSOP) (Cruz-Jentoft et al., 2010). Nonetheless, it is 
clear that the major risk factors for sarcopenia are chronological age (obviously) and 
long-term care settings (Cruz-Jentoft et al., 2014), with the prevalence in community 
settings being considerably lower. Irrespective, the consequences of muscle wasting 
and weakness engender numerous physiological and psycho-social impacts i.e. i) 
inability to independently perform tasks of daily living, ii) frailty and increased risks of 
falls, iii) loss of independent living and related depression/social isolation, iv) physical 
 4 
inactivity (sedentarism), v) increased risk of chronic diseases, vi) increased risk of all-
cause mortality; (Arango-Lopera et al., 2013).  
 
Thus, arises the question: why does sarcopenia have such devastating global health 
effects? Clearly, frailty arises from impairments of skeletal muscles’ function to 
generate voluntary movement; simply put, loss of mass and function limits muscles’ 
fundamental capacity to generate force. However, skeletal muscle is also important in 
regulating whole-body metabolic health. For instance, muscle is responsible for the 
majority of post-prandial glucose disposal (DeFronzo et al., 1985; Shulman et al., 
1990) and in supplying substrates for other tissues energy needs (e.g. glucogenic 
amino acids for hepatic gluconeogenesis) during fasted periods, with muscle protein 
stores being replenished upon intake of dietary protein (M S Brook et al., 2016). A 
failure in these processes can lead to perturbations in homeostasis e.g. 
hyperglycaemia or muscle catabolism. Moreover, physical activity, the levels of which 
decline with age (McPhee et al., 2016), can also protect against muscle atrophy 
through promotion of muscle hypertrophy/strength/fatigue resistance. On this basis, it 
has been suggested that maintaining physical activity with ageing is important since: 
i) exercise can positively influence muscle mass/function and metabolic health 
(notably, interventions do not always affect the trajectory of chronic diseases (Uusitupa 
et al., 2009)), and ii) physical activity stimulates secretion of so-called “myokines” 
purported to underlie many of the trans-organ health benefits of exercise (Pedersen 
and Febbraio, 2008) (although with little-to-no evidence of how ageing affects these 
functions). It is not a new observation that muscles secrete factors that act in an 
auto/para/endocrine manner with humorally acting “protein” factors having been 
suggested to influence muscle glucose uptake nearly a quarter of a century ago (Gao 
et al., 1994). Moreover, it is logical that cross-talk between muscle and adipose/hepatic 
tissues exists to regulate the established liberation of energy substrates during 
exercise; this is no different from the adrenal glands releasing catecholamines to 
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promote lipolysis. Indeed, while there is much excitement in relation to myokines and 
how they may impact sarcopenia (and chronic diseases) - especially those targeting 
myostatin – results to date in relation to neuromuscular outcomes have been largely 
disappointing. This is perhaps unsurprising as upregulation of myostatin is likely not a 
feature of ageing (Ratkevicius et al., 2011; Ryan et al., 2017), and anti-myostatin 
therapies fail in animal models of neuromuscular decline because the myostatin 
pathway has already been adaptively shut-down (Saitoh et al., 2017). The remainder 
of this review will maintain a focus on the two key areas of age-related muscle atrophy 
and dysfunction and their analytical quantification in humans; namely: 1) whole-muscle 
and fibre atrophy and mechanisms, and 2) neuromuscular degeneration, fibre 
hypoplasia and their mechanisms.  
 
2. Muscle fibre atrophy in humans: quantification, evidence and 
mechanisms 
 
2.1 Quantification of MPS and MPB in humans 
In order to quantify muscle protein turnover in humans to delineate the effect of ageing 
upon skeletal muscle homeostasis, sensitive analytical methods are required to 
measure MPS and MPB. This has been achieved through the application of stable 
isotopically labelled amino acids (AA; using 2H, 13C, 15N, and 18O) to “trace” the 
movement of label from the blood and into and out of tissues and proteins. These 
heavy isotopes are typically distinguished from their more abundant lighter isotope by 
mass spectrometric techniques (effectively expensive weighing instruments). A 
simplified overview for those unfamiliar with these approaches follows. Traditionally, 
MPS is determined from muscle sampling (biopsy), extracting the tracer bound protein 
(the product) and measuring the amount of ‘label’ (e.g. the heavier isotope) 
incorporated over time in relation to the precursor, typically the enrichment of the tracer 
in the bloodstream/muscle over time (e.g. for 13C phenylalanine), or enrichment of the 
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deamination product in the case of AA such as leucine (KIC) that are deaminated in 
muscle. This is the so-called “precursor-product” relationship, where the precursor 
labelling relates to the product labelling. In contrast, MPB is typically quantified via 
dilution of a tracer across a tissue, organ, or limb. This is conducted by tracking the 
enrichment and concentration of the tracer (usually in a steady state), ideally in the 
artery supplying the tissue, and measurement of its dilution in the vein draining the 
organ or limb. For instance, an increased venous dilution of the tracer (through AA 
being released from the muscle) would indicate elevated MPB (Ra- rate of 
appearance). It is also possible to determine net protein balance (NB) by comparing 
identically timed AA concentrations in the main artery/vein feeding/draining the 
limb/organ (as a product of arterial blood flow), which provides the “net” anabolic or 
catabolic state of a given limb muscle mass. NB in a steady-state is a result of the 
balance between the rates of MPB and MPS, therefore with measures of Ra and NB, 
rates of MPS (Rd- rate of disappearance) can be determined. These techniques have, 
and continue to, generate the majority of insight into the impact of age on human 
muscle proteostasis. We further refer readers to (Biolo et al., 1995b; Wilkinson, 2016; 
Wilkinson et al., 2017a; Wolfe and Chinkes, 2005; Zhang et al., 2002) for more in depth 
technical insight. 
2.2 MPS and MPB in human ageing 
Muscle mass is regulated by the dynamic balance between MPS and MPB, with the 
major two environmental influences on these processes being food intake and physical 
activity. The intake of dietary protein influences MPS by driving the stimulation of MPS 
(Atherton et al., 2010a), while insulin suppresses MPB (mediated by insulinogenic AA 
and/or carbohydrates: (Greenhaff et al., 2008)). This acts to replenish muscle protein 
lost during catabolism in the fasted state (P.J. Atherton et al., 2016) e.g. due to efflux 
of muscle AA to support hepatic gluconeogenesis. It has been known for over 30 years 
that AA represent the primary nutrient driver behind feeding induced increases in MPS 
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(Bennet et al., 1989), with this stimulation almost exclusively driven by the essential 
AA’s (EAA), in particular leucine (Smith et al., 1998, 1992, Wilkinson et al., 2017b, 
2013). These anabolic responses to dietary protein are both dose dependent and 
transient in nature, where maximal MPS responses are achieved with 10 g of EAA in 
younger individuals (Atherton et al., 2010a; Cuthbertson et al., 2005), and with 
exercise being able to extend the duration of this anabolic response (beyond 2-3 h) 
when performed alongside intake of dietary protein of free EAA mixtures (Cuthbertson 
et al., 2006; Miller et al., 2005; Phillips et al., 1997). This creates a situation where, 
across a diurnal cycle, MPS=MPB and muscle mass remains constant (Figure 1). The 
importance of physical activity/movement in regulating muscle mass homeostasis is 
best exhibited in relation to the impact of complete immobilization (e.g. casting, bed 
rest) or what we would term “partial immobilization” (e.g. reduced movement due to 
sedentary behaviour and limited recreational activity (Philip J Atherton et al., 2016a; 
Breen et al., 2013a; de Boer et al., 2007a, 2007b)), which induce rapid muscle atrophy. 
As such, for muscle atrophy to occur, MPB must exceed MPS via a decrease in MPS 
and/or increase in MPB and this must to some extent be dysregulated in ageing. The 
search for the environmental drivers of dysregulated muscle proteostasis regulating 
age-related muscle loss remains hotly researched (Philip J Atherton et al., 2016b).  
It follows that the burning question remains; what happens to these tightly regulated 
homeostatic processes in relation to age-related skeletal muscle atrophy? Ground 
breaking work more than 10 years ago helped to develop the idea of “anabolic 
resistance” to explain the phenomenon of age related muscle loss. The premise being 
that increases in MPS and suppressions in MPB in response to the key environmental 
factors regulating muscle maintenance i.e. food intake (Cuthbertson et al., 2005) and 
exercise (Kumar et al., 2009) are blunted compared to younger people. While this 
remains a contentious subject with mixed results from studies comparing young and 
old (Paddon-Jones et al., 2004; Symons et al., 2009, 2007), recent meta-analyses 
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supports the existence of anabolic resistance with age (Moore et al., 2015; Wall et al., 
2015). Indeed, an early study identified no age-related differences in 
basal/postabsorptive protein turnover (Volpi et al., 2001); but has failed to be repeated. 
Therefore, the potential scenarios are: i) anabolic resistance is the major driver of age-
related muscle loss, ii) MPS and MPB are not key factors – which seems highly 
unlikely, or iii) since sarcopenia is a slow and incipient process, the aetiology cannot 
be captured by short-term metabolic studies over a few hours.  
In relation to this latter point, a criticism of short-term tracer studies has been the ability 
to extrapolate the findings of acute tracer studies performed over several hours in a 
controlled environment to that of free living real life situations. For example, acute MPS 
responses to resistance exercise training (RET) do not correlate with the end-point it 
aims to relate to – changes in mass with chronic RET (C. J. Mitchell et al., 2015). 
However recent technical developments in terms of stable isotope tracer techniques 
have allowed for the chronic measurement of protein turnover over days, weeks and 
months through the use of the stable isotope tracer deuterium oxide (D2O) or “heavy 
water”. Administered orally, the deuterium from D2O is incorporated onto different 
substrates, such as AA, at stable C-H positions through biological reduction during de 
novo synthesis, allowing rates of skeletal muscle protein turnover to be measured. 
Furthermore, the rapid equilibrium of D2O across tissue pools, combined with slow 
turnover of both the body water pool and skeletal muscle proteins, this technique is 
perfectly suited for the measurement of protein turnover over periods of days-weeks 
and months, overcoming the limitation of more traditional tracer techniques (Brook et 
al., 2015; Matthew S. Brook et al., 2016; Wilkinson et al., 2015, 2014). Using these 
techniques, the presence of anabolic resistance to the trophic effects of exercise in 
ageing has been confirmed, with significantly reduced rates of cumulative MPS in 
response to 6-weeks of unilateral RET compared to young, which accompanied 
blunted mass gains (Matthew S. Brook et al., 2016). Nonetheless, it remains a leap of 
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faith to suggest that anabolic resistance to RET is responsible for age-related muscle 
loss. That being said, we speculate that by extension, even habitual movement, which 
normally acts to help maintain muscle mass (even in youth), becomes a less effective 
cue for muscle maintenance in older people. 
In terms of the contribution played by MPB to age-related muscle loss, this has been 
more difficult to ascertain due to myriad technical challenges associated with 
measuring MPB. While techniques such as fractional break down rate (FBR) (Zhang 
et al., 2002) and A-V balance (Biolo et al., 1995a) can provide estimates of MPB, they 
rely on numerous assumptions. For instance, with A-V balance, there are assumptions 
of tissue specificity (i.e. that the sampled vein is only draining muscle tissues) while 
these methods also rely on other variable physiological measures (blood flow), that 
are technically challenging. Hence there is a lack of studies available on MPB and 
ageing. That being said, it has been observed that in older adults there is blunted 
inhibition of MPB in response to increases in plasma insulin equivalent to that of post-
prandial levels (Wilkes et al., 2009) – i.e. an “insulin resistance of protein metabolism”. 
Therefore, it is assumed that the combination of suppressed inhibition of MPB by 
insulin combined with blunting of MPS (in response to dietary protein and movement), 
exacerbates anabolic resistance in older adults, and presumably muscle atrophy. 
Another physiological driver of age-related muscle atrophy is thought to be physical 
inactivity, since older age is associated with moving less and abstention from 
recreational sporting activities (McPhee et al., 2016). Indeed, it is already well-
established that either complete or partial immobilization causes muscle atrophy, 
irrespective of age. For example, unilateral limb immobilization leads to rapid muscle 
atrophy even in young healthy adults, with ~5% reduction in muscle CSA after only 14 
days (de Boer et al., 2007b) with recent evidence suggesting that much of this loss 
occurs within the first few days (Wall et al., 2014). This loss of mass is accompanied 
by anabolic resistance; vis-à-vis, decreases in both the rate of post-absorptive MPS 
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(de Boer et al., 2007a) and a blunted response to nutrition (Glover et al., 2008). Even 
more strikingly, merely reducing daily activity (step count) induces anabolic resistance 
(Breen et al., 2013b) and causes muscle atrophy. Since older people tend to move 
less, we would suggest that this, coupled to age-related anabolic resistance, are key 
drivers of sarcopenia. Nonetheless, whether older individuals are more ‘susceptible’ to 
immobilization related muscle loss, remains controversial. Indeed, while one early 
study showed older adults losing muscle at twice the rate of younger people (Kortebein 
et al., 2007), others have shown lower levels of muscle mass loss in older vs. younger 
individuals over the same period of immobilization (~3.5% vs ~1.5% reduction in CSA 
in young and old respectively; (Dirks et al., 2014; Wall et al., 2014). This controversy 
aside, older adults do seem to have a reduced capacity to recover muscle loss 
completely, despite supervised rehabilitation (Suetta, 2017; Suetta et al., 2013). Age-
related muscle atrophy, therefore, appears to be caused by a combination of 
behavioural and physiological interacting factors, from resistance to anabolic stimuli, 
leading to suppressed MPS and inhibited suppression of MPB, to inactivity and 
immobilization, and perhaps with an exacerbation of atrophic responses and a failure 
to fully recover.  
 
2.3 The molecular regulation of muscle protein turnover and atrophy in human ageing 
In the case of the molecular regulation of dysregulated MPS and MPB with ageing, a 
number of studies have aimed to delineate the sites of molecular dysregulation: i) in 
response to nutrition, ii) in response to exercise, and iii) in relation to the upstream 
drivers of these processes. In relation to the regulation of muscle nutrient sensing and 
signalling (and potential dysregulation in ageing) by nutrients, EAA, and in particular 
leucine (Atherton et al., 2010b; Wilkinson et al., 2013), while also being a substrate for 
MPS (i.e. a proteinogenic AA) are also a signalling molecule (Bonfils et al., 2012; Han 
et al., 2012; Moro et al., 2016). For example, leucyl tRNA synthetase (enzyme that 
attaches leucine to its cognate tRNA) binds to GTPases, known mediators of mTORc1, 
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activating mTOR signalling (Bonfils et al., 2012; Han et al., 2012). Due to this need for 
both substrate and sensing, it has been proposed that reductions in AA delivery to the 
muscle may impair this intracellular signalling and hence MPS (Moro et al., 2016). 
Initially it was proposed that impaired dietary absorption, through increased splanchnic 
AA extraction in older adults, might contribute to reduced AA delivery to muscle (Boirie 
et al., 1997; Moreau et al., 2013). However, hyperaminoacideamia following large 
doses of protein or AA is actually higher than, and more prolonged, in older adults 
(Koopman et al., 2009; W. Mitchell et al., 2015a, 2015b), suggesting that impaired 
digestion/absorption of AA is not a limiting factor in MPS. Since ageing leads to 
reductions in limb blood flow (Skilton et al., 2005) with associated blunting of post-
prandial micro and macro vascular blood flow to muscle (Mitchell et al., 2013), altered 
delivery of AA could still impact muscle anabolism. In support of this, work from one 
group showed muscle anabolism could be impaired by reducing microvascular blood 
flow (MVF; using NOS inhibitor L-NMMA; (Timmerman et al., 2010a)), and augmented 
by increasing MVF (using the NO donor SNP; (Timmerman et al., 2010b). However, 
more recent work has shown that enhancement of microvascular responses to feeding 
in older men using exercise (Phillips et al., 2015), cocoa flavanols (Phillips et al., 2016) 
and the NOS precursor arginine (W. K. Mitchell et al., 2015), did not improve muscle 
anabolism, suggesting AA delivery is unlikely a factor in age induced atrophy. This is 
in line with work showing that the post-prandial intracellular concentrations of AA 
actually tend to be higher in older individuals than young (Paddon-Jones et al., 2004), 
presumably due to compromised clearance by MPS. Therefore, impaired intracellular 
induction or propagation of mTORC1 signalling is the most likely candidate, in line with 
early findings of impaired mTORC1 substrate phosphorylation in older vs. younger 
muscle (Cuthbertson et al., 2005; Guillet et al., 2004). In contrast, nothing is known of 
how “insulin resistance of protein metabolism” is regulated; we postulate that impaired 
age-related insulin resistance is associated with impaired cross-talk to anti-catabolic 
pathways. This notion could be viewed as akin to the dysregulation of signalling 
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between the insulin receptor and GLUT4 translocation (and thereby glucose uptake).  
 
In terms of sensing movement/exercise, it is becoming increasingly evident that 
intrinsic mechano-sensitive signalling pathways act to increase mTORC1 activity post 
exercise (Hornberger et al., 2006; O’Neil et al., 2009). However it has been shown that 
p70S6K signalling is blunted in response to acute exercise in older age (Fry et al., 
2011; Kumar et al., 2009), as well as being impaired temporally in response to 6-weeks 
RET (Matthew S. Brook et al., 2016) thus reducing translational efficiency (meaning 
the activity of pathways involved in co-ordinating the rate of mRNA translation). 
Interestingly, in the same study aspects of translational capacity; RNA content and 
ribosomal biogenesis, were also investigated, with blunted expression of rDNA 
transcription factors cMyc and TIF1a, alongside blunted increases in the indices of 
translational capacity (RNA:DNA and RNA:Protein ratios) being observed in the older 
adults in response to RET (Matthew S. Brook et al., 2016). This suggests that impaired 
ribosomal biogenesis and capacity for MPS in older adults may also be a key factor 
underlying anabolic resistance. It is not only RNA which may be impaired in the skeletal 
muscle of older adults. It has been posited that skeletal muscle satellite cells (SC), 
which provide an essential role for the regeneration and repair of muscle fibres through 
the provision of additional myonuclei to the mature post-mitotic muscle cells (Lepper 
et al., 2011), may also play an important role in muscle growth (in response to RET) 
and muscle mass maintenance (Snijders and Parise, 2017). With evidence of a decline 
in skeletal muscle SC content with age (Verdijk et al., 2014), it may be that this decline 
in concert with a decline in SC function with age could be a factor in the inability to 
maintain muscle mass (Snijders and Parise, 2017). However based on the current 
models used (pre-clinical models associated with genetic/irradiated ablation of SC; 
(McCarthy et al., 2011; Rosenblatt et al., 1994)) to assess the role of SC in skeletal 
muscle growth and ageing, and the continued conflicting findings arising from these 
experiments (Blaauw and Reggiani, 2014), it remains unclear as to the importance of 
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SCs in the maintenance of muscle in older age and in relation to muscle hypertrophy 
with RET.  However, with new, novel stable isotope tracer techniques available for 
directly measuring both RNA and DNA synthesis in muscle (Brook et al., 2017), the 
overall influence of ribosomal biogenesis and satellite cells in relation to anabolic 
resistance can also begin to be determined.  
 
Sarcopenia is not only associated with a loss of mass, but also a loss of muscle quality, 
associated with an increase in extra and intra-myocellular lipid deposition (Delmonico 
et al., 2009). This increase in intracellular muscle lipids has been linked to the 
development of insulin resistance, and in turn, could impact muscle protein turnover. 
In relation to this, it has been shown i) that lipid induced insulin resistance in younger 
adults leads to a reduction in MPS in response to AA, with suppression of mTORc1 
signalling (Stephens et al., 2015), and ii) that obese adults exhibit anabolic resistance 
in MPS to nutritional cues (Murton et al., 2015). Not only can lipid infiltration lead to 
insulin resistance that could relate to dysregulated proteostasis in ageing, but it has 
also been linked to the development of inflammation (Kalinkovich and Livshits, 2017; 
Rivas et al., 2016). A number of studies have identified an association between 
inflammatory markers and loss of muscle mass (Cesari et al., 2005; Visser et al., 
2002), e.g. with a negative correlation between the inflammatory marker CRP and 
muscle mass being observed in older women (Wåhlin-Larsson et al., 2017). Whilst the 
mechanisms are unclear, studies in rats have shown that the reduction of low grade 
inflammation can restore post-prandial muscle anabolism (Rieu et al., 2009). Recent 
work has purported that CRP itself may act as a catabolic regulator in muscle by 
inhibiting mTORC1 via depression of upstream signalling through AKT/PI3K, and/or 
an increase in intracellular energy stress via upregulation of AMPK which can directly 
inhibit mTORc1 (Wåhlin-Larsson et al., 2017). In sum, while the upstream regulators 
of anabolic resistance are ill defined, dysregulated lipid handling is a candidate.  
 
 14 
Finally, the production of reactive oxygen and nitrogen species (RONS) and oxidative 
damage has long been thought of as a potential mechanism of age-related muscle 
atrophy through the radical theory of ageing, whereby RONS damage proteins, lipids 
and DNA leading to dysfunction of the tissues (Harman, 1956). Moreover, an essential 
role has been proposed for ROS in regulating the IGF-AKT-mTOR signalling pathway 
(Nacarelli et al., 2015), which in turn can directly impact control of muscle protein 
turnover. Although much of this work has been performed in genetic pre-clinical 
models (e.g. knocking out genes involved in scavenging free radicals), a recent human 
study looking at levels of protein carbonylation - a marker of oxidative damage - in 
muscle showed that levels of protein carbonyls increased with age, but no difference 
was observed between those designated as sarcopenic and non-sarcopenic (Beltran 
Valls et al., 2015). Therefore the contribution of RONS to age related muscle decline 
remains debatable, while the use of antioxidant therapies has proved largely 
unsuccessful (Deane et al., 2017), and with antioxidants potentially having adverse 
effects on muscle (Gomez-Cabrera et al., 2008). As such, while their role is difficult to 
define in humans, there is little evidence that redox imbalances are key drivers of age-
related muscle atrophy, nor in response human disuse atrophy (Glover et al., 2010). 
 
In sum, whilst there are many other aspects of physiology which have been proposed 
to contribute to skeletal muscle atrophy with age, such as declines in mitochondrial 
content and function with age (Johnson et al., 2013; Rooyackers et al., 1996) and 
disturbances to the hormonal mileiu (Basualto-Alarcon et al., 2014), there is always 
going to be research striving to find this “magic bullet” compound or intervention to 
combat age-related skeletal muscle wasting. Therefore, more research is needed to 
determine the location and mechanisms of the road-blocks between the key 
environmental cues for muscle maintenance (i.e. movement and food) and the 
regulation of muscle homeostasis. Nonetheless, there is clear evidence of metabolic 
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inflexibility in protein metabolism in older age; Figure 1 represents a summary of the 
potential major drivers of age-related muscle atrophy in humans, as discussed above. 
 
3. Muscle fibre loss in humans: quantification, evidence and mechanisms 
 
3.1 Quantification of muscle fibre number (hypoplasia) in older humans 
Beyond muscle atrophy, the second, and likely inter-connected mechanism of whole 
muscle atrophy is that of muscle fibre loss (hypoplasia). The gold-standard 
measurement is direct anatomical estimates obtained from cadaveric studies, although 
for obvious reasons these studies are rare. Among the first human studies of this 
nature was from Lexell et al (1983) who compared data from 12 cross sections of 
autopsied vastus lateralis (VL) of ~30 and ~72 year old men (Lexell et al., 1983). The 
mean total muscle size of the VL was 18% smaller in the old. The difference in total 
muscle size was purported to be accounted for by a marked reduction in the number 
of myofibres in the older muscle (478,000 vs. 364,000). The same group later 
expanded this evidence with a further 43 full cross sections of VL, from men aged 15-
83 years, and noted a reduction in total muscle size from 20 to 80 years of 40%, largely 
associated with a 39% reduction in the number of fibres across the same age range 
(Lexell et al., 1988). It is worth noting that muscle fibre loss did not account for the 
entirety of total muscle loss, as smaller (i.e. atrophic) fibres were also observed in older 
muscles, in addition to the fact that there was a ~20% greater amount of non-
contractile material in the old muscle, which would artificially inflate total muscle CSA.   
 
The nature of such detailed anatomical counts and estimates explains why they are so 
rare; however further studies have made estimates by dividing mean fibre CSA into 
total muscle CSA. In a 12-year longitudinal study of nine men, Frontera et al (2000) 
reported an average 14.7% decrease in quadriceps CSA (from 65 to 77 years) with no 
decrease in individual fibre CSA, suggesting fibre loss was responsible for the total 
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whole muscle atrophy (Frontera et al., 2000). In relation to muscle loss and force 
producing capacity, Jubrias et al (1997) reported a 21% decline in total muscle size 
between 65-80 years, with a 39% decrease in force, equating to a 21% decline in 
specific force (i.e. force normalized to muscle size) (Jubrias et al., 1997). Thus, the 
age-related decreases in force producing capacity cannot be explained entirely by a 
decrease in muscle size - likely suggesting deleterious neuromuscular remodelling. 
Indeed, although alterations in older muscle fibres independent of size will reduce their 
force generating capacity (Ochala et al., 2007), denervated fibres are present in older 
human muscle (Spendiff et al., 2016), which contribute to total muscle size but their 
lacking of innervation would mean a failure to contribute to force generating capacity.  
 
More recently, in a study estimating VL fibre number from biopsy and total muscle 
CSA, data from 31 young (~22y) and 40 old (~72y) men and women estimated the 
age-related difference in total muscle size was due, in almost equal amounts, to fibre 
atrophy and a reduction in the number of fibres in the old (McPhee et al., 2018). 
However this evidence is not equivocal, as the same methods showed the difference 
in fibre number in bicep brachii (BB) between young (21±2 years) and old (82±2 years) 
to be minimal (253,000 vs 234,000) (Klein et al., 2003). This discrepancy may be 
explained by the differential response to ageing observed in different muscles 
(Pannérec et al., 2016; Piasecki et al., 2018b), and the minimal age-related loss of 
CSA in BB (Janssen et al., 2000). Moreover, Van Loon and colleagues showed that 
up to 100% of age-related whole muscle atrophy in the VL could be explained by fibre 
atrophy without the need for fibre loss – based on MRI of thigh muscles and 
determining fibre area of related muscle biopsies (Nilwik et al., 2013), although older 
fibre CSA reported here were around 25% larger than previously reported areas (Gouzi 
et al., 2013). As such, it remains controversial as to the contributions of atrophy and 
fibre loss in whole muscle atrophy. We suggest it is highly likely taking all together that 
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both are key factors at play in sarcopenia, and that existing data are compromised by 
both methodological and physiological differences. 
 
Further indirect evidence of age-related fibre loss comes from the maximal compound 
muscle action potentials (CMAP) of young and old muscle, whereby motor neurons 
serving the muscle of interest are electrically stimulated in order to elicit a maximal 
contraction. The electrical activity of this contraction can be measured via 
electromyography (EMG) to provide an estimate of the amount of contractile material 
contained within the recording limits of the EMG electrode. Although not without its 
limitations (Piasecki et al., 2018a), this method consistently shows older muscle has a 
smaller CMAP than young in a range of muscles, including tibialis anterior (TA) (McNeil 
et al., 2005; Piasecki et al., 2016a), soleus (Dalton et al., 2008), BB (Power et al., 
2012), and VL (Piasecki et al., 2016), with a further study showing no age-related 
difference in TA (Hourigan et al., 2015). The assumption here is that the relatively small 
volume of muscle recorded from is constant, then the older muscle contains a reduced 
amount of contractile material, probably as a result of fewer and smaller muscle fibres, 
combined with an increased number of denervated fibres (see below).  
Clearly, differences in experimental design, technical challenges of methodologies, 
variation between individual muscles, and environmental influences between subjects 
are all considerations leading to the apparent discrepancies between studies. 
Nonetheless, once again, it would generally appear that both muscle fibre atrophy and 
the loss of fibres are highly likely to be factors in age-related atrophy of whole-muscles. 
 
3.2 Quantification of motor unit number in older humans 
Loss of muscle fibres is associated with the age-related loss of motor units (MU) 
(Faulkner et al., 2007; Hepple and Rice, 2016; Piasecki et al., 2016b). Described as 
the last functional unit of the motor system, the human MU comprises a cell body in 
the ventral horn of the spinal cord, the alpha motor neuron and all of the muscle fibres 
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it innervates. Again, post mortem anatomical studies have provided a wealth of 
information on the effects of age; with there being a progressive decrease in the 
number of cell bodies in spinal cord sections aged over 60 years, and those aged over 
75 years having 30% fewer serving the lower limbs than young (Kawamura et al., 1977; 
Mittal and Logmani, 1987; Tomlinson and Irving, 1977). Human in vivo studies utilising 
EMG techniques have also shown an age-related decline in MU number, in small 
(Galea, 1996), and larger muscles (McNeil et al., 2005; Hourigan et al., 2015; Piasecki 
et al., 2016a; Piasecki et al., 2016b). The loss of a MU will leave a muscle fibre 
denervated and more susceptible to atrophy and eventually loss. However, many 
fibres will be re-innervated by a nearby surviving axon. These axonal sprouts originate 
from non-myelinated areas of the axon and can ‘rescue’ a denervated fibre in an 
attempt to preserve muscle mass, termed MU remodelling (Luff, 1998; Piasecki et al., 
2016b) (Figure 2). Furthermore, recent evidence suggests that a failure to reinnervate 
denervated fibres distinguishes sarcopenic from non-sarcopenic older men (Piasecki 
et al., 2018b), supporting the notion that this remodelling process occurs into older age 
but excessive fibre loss occurs when reinnervation can no longer sufficiently 
compensate for denervation. Thus, older muscle tends to comprise MU’s that are fewer 
in number and larger in size (in terms of fibre ratio) up to a certain point/age, when 
fewer and smaller MUs become more prevalent. Interestingly this remodelling process 
appears to be muscle specific, and more ‘successful’ in the TA compared to VL 
(Piasecki et al., 2018b). Given age-related alterations in MU size (increased fibre ratio) 
it is unsurprising to find that force steadiness (the ability to match a desired force) is 
impaired in older people (Dideriksen et al., 2012; Laidlaw et al., 2000), indicating there 
are important functional consequences of fibre loss and MU remodelling that reach 
beyond the loss of muscle size and strength.  
 
Although the evidence strongly suggests an association between age associated MU 
remodelling and fibre loss, the proposed mechanisms are not entirely in agreement. 
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Does the problem initially occur at the cell body in the spinal cord, somewhere along 
the axon, or does it originate within the myofibre, causing denervation and propagating 
along the alpha motor neuron in a retrograde manner? It is thus unclear if denervation 
is a cause or a consequence of fibre loss with further research clearly needed to 
address this. 
 
3.3 Putative mechanisms of neuromuscular remodelling in older humans 
The majority of the more detailed mechanistic data has been generated from rodent 
models (Deschenes, 2011; Gonzalez-Freire et al., 2014; Tintignac et al., 2015) and 
has focused on the neuromuscular junction (NMJ); the synapse between motor neuron 
and muscle fibre. The relationship of the NMJ and muscle fibre in this regard may be 
described in 3 stages. Firstly, with complete innervation, myonuclei close to the 
synapse express genes involved in NMJ maintenance (MuSK), which are suppressed 
in non-synaptic myonuclei. Secondly, with initial denervation proteasomal pathways 
are up regulated in all myonuclei. Thirdly, after prolonged denervation, there is an 
inhibition of autophagy and an increase in protein synthesis (via mTORC1) (Tintignac 
et al., 2015) (Figure 2). Therefore a denervated fibre will immediately begin to atrophy, 
but will survive for an ill-defined amount of time, and these have been observed in a 
number of human biopsies (Lexell and Taylor, 1991; Spendiff et al., 2016; Zampieri et 
al., 2015). Further associations of age-related denervation and impaired reinnervation 
have been established in animal models, including alterations in oxidative stress 
(Jackson and Mcardle, 2016; Vasilaki et al., 2017), dysregulation of sterol metabolism 
in the nervous system (Pannérec et al., 2016), conversion of voltage-gated sodium 
channels on fibre membranes (Rowan et al., 2012) and a reduction in the number of 
key maintenance proteins such as PGC1-a (Gouspillou et al., 2013). As previously 
mentioned the number of SCs is decreased with age (Verdijk et al., 2014), and their 
involvement extends beyond the maintenance of the fibre; acting as a source of post-
synaptic myonuclei their reduction results in reduced maintenance of this region and 
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ultimately degeneration of the  NMJ (Liu et al., 2017), and poor fibre regeneration 
following reinnervation (Dedkov et al., 2001). Additionally, terminal Schwann cells are 
implicated in the remodelling of MUs by initiating and guiding axonal sprouts, and are 
known to develop impairments with increasing age (Saheb-Al-Zamani et al., 2013) 
(Figure 2). However, again - it is not entirely clear in all cases if these associations 
result of a cause or a consequence of denervation.  
Furthermore, in many animal studies of this nature the measured response to 
denervation has followed nerve sectioning or ligation, therefore caution must be 
employed given that complete muscle denervation may promote the onset of different 
pathological pathways to that following repeated cycles of de/reinnervation of 
individual fibres. 
 
In human studies, lifelong exercise has been suggested to minimise muscle loss 
(Mckendry et al., 2018) and prevent the age-related loss of MU number, and 
presumably fibre number in the TA of old (64 years) (Power et al., 2010) but not very 
old (79 years) athletes (Power et al., 2016). However a further study found masters 
athletes (69 years) had a similar number of MUs in the TA as age matched controls 
(Piasecki et al., 2016a). Although it is unlikely that exercise preserves the number of 
MU, it may improve the ability to reinnervate denervated fibres in order to preserve 
muscle fibre number, however this largely comes from biopsy studies which show 
increased fibre type grouping in master athletes (Zampieri et al., 2015). Although 
interesting, this grouping is indicative of a shift in fibre type composition (type I/II; an 
unbalanced ratio of fibre type composition will increase the probability of observing 
increased fibre type groupings) and does not directly prove the grouped fibres belong 
to the same MU. What is clear is that the notion of motor unit plasticity relating to the 
prevention of muscle fibre loss in humans is disproportionately underexplored and 
possible therapeutic targets in ageing (and diseases) warrants further investigation.  
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4. Conclusions 
The present review details the major two influences upon loss of muscle mass and 
function with age: muscle fibre atrophy and muscle fibre loss. It is reasonably clear that 
both of these elements play a role in regulating muscle atrophy and dysfunction at the 
level of whole-muscle/groups. Nevertheless, few if any research groups focus upon 
both of these facets simultaneously in humans, nor the prospect of them being inter-
related processes (denervation leading to atrophy and/or vice-versa). While this 
presents experimental challenges, only will investigating these processes 
simultaneously shed light on the mechanisms of human sarcopenia and dysfunction. 
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Figure 1. Summary of the purported mechanisms driving anabolic resistance and muscle atrophy in older age. 
In young adult muscle the response to anabolic stimuli such as mechanical sensing and feeding, provides stimulation of MPS and inhibition of 
MPB regulated primarily via control through mTORc1 signalling helping to maintain muscle mass. In older age, muscle becomes resistance to these anabolic 
stimuli, leading to impaired MPS and suppressed inhibition of MPB, consequently leading to the onset of atrophy. The factors driving this anabolic resistance 
and atrophy are not well described, however a number of theories have been proposed as highlighted in the figure and discussed within this review. 
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Figure 2. Summary of denervation induced muscle fibre hypoplasia Top: With normal innervation, myelinated axons communicate with the muscle fibre 
at the NMJ. Each neuron and all muscle fibres connected to it via the NMJ are part of the same MU. Denervated fibres may be reinnervated by schwann cell 
guided axonal sprouting, or they may atrophy and eventually be lost. Bottom: With normal innervation, electrical activity from action potentials suppress NMJ 
maintenance genes in non-synaptic nuclei, with expression maintained in synaptic nuclei via agrin-MuSK signalling. Immediately post denervation proteasomal 
degradation is increased, then decreased with prolonged denervation combined with an increase in protein synthesis.    
 
 
